O3‐04–05: Clinical trials of bapineuzumab, a beta‐amyloid‐targeted immunotherapy in patients with mild to moderate Alzheimer's disease
The DOI matches its Crossref record.
Abstract
Immunotherapy has been shown to reduce beta-amyloid (Aβ), a protein that accumulates in Alzheimer's disease (AD) brain and is central to the neuropathology of AD. Preclinical studies have shown that immunotherapy with antibodies raised to the N-terminus of Aβ reduce amyloid burden and have favorable effects on synaptic density and memory. A phase 1 study of bapineuzumab, a fully-humanized monoclonal antibody raised against the N-terminus of Aβ, demonstrated single dose safety and tolerability of bapineuzumab in patients with mild-to-moderate AD. Based on phase 1 results, a phase 2, multiple ascending dose study of bapineuzumab was initiated. This randomized, multicenter, double-blind study in patients with mild-to-moderate AD was designed to explore the potential efficacy and safety of bapineuzumab at various doses compared with placebo. Patients were randomized to receive either 0.15 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg bapineuzumab or placebo in a 1:1 fashion. Patients are being followed for 18 months to determine the safety of bapineuzumab, as well as bapineuzumab's efficacy as measured by cognitive measures (ADAS-Cog; NTB) and functional assessments (DAD). Additional analyses of brain volume by MRI, amyloid brain imaging, and measurement of cerebrospinal fluid Aβ and tau protein levels are planned. Information regarding the bapineuzumab development program will be presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
“…evidenced a mean significant decrease in CSF t-tau concentrations (Gilman et al., 2005) in vaccinated AD cases versus placebo-treated controls, however, the anti-Ab passive immunization trial AAB-001 showed no statistically significant effect on CSF tau concentrations (Grundman and Black, 2008).”
BackgroundCan Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Pitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.018 · Cited by 134
“Passive immunization, in which Aβ-recognizing antibodies are given to augment patient titers, shows promise in mouse models and is currently in Phase III human trials (Bard et al., 2000; Grundman and Black, 2008).”
Background
Metadata
- Authors
- Grundman, M., & Black, R.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2008-07
- Volume
- 4
- Issue
- 4S_Part_5
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2079845730
- Cited by
- 30
- References
- 0
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: O3‐04–05: Clinical trials of bapineuzumab, a beta‐amyloid‐targeted immunotherapy in patients with mild to moderate Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2008.05.436
- The paper
- Grundman, M., & Black, R. (2008). O3‐04–05: Clinical trials of bapineuzumab, a beta‐amyloid‐targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2008.05.436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.